A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 40
- Population
- ALL · 55 Years
- Duration
- 2016-10-28 to 2018-04-10
- Intervention
- Elamipretide
- Comparator
- Not reported
- Outcomes measured
- Change From Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA) — Day 0 (Baseline to Day 7, and to…; Change From Baseline in Mean Low Luminance Best-Corrected Visual Acuity (LLBCVA) — Baseline to Day 7, Week 4, Week 8, W…; Change From Baseline in Mean Dark Adaptometry — Baseline (Day 0) and Week 24; Mean Treatment Compliance (%) of Administration of Subcutaneous Elamipretide — Baseline through Week 28; Mean Number of Home Health Visits to Administer Elamipretide — Baseline (Day 0) through Week 24; Change From Baseline in Mean Area of Geographic Atrophy by Fundus Autofluorescence — Baseline (Day 0) to Week 24; Change From Baseline in Mean Area of Geographic Atrophy as Measured by Spectral-Domain Optical Coherence Tomography (SD…; Change From Baseline in Mean Reading Acuity Test: With Standard Luminance — Baseline and Weeks 4, 8, 12, 16 20, 24 and…; Change From Baseline in Mean Reading Acuity Test: Low Luminance — Assessed at screening, baseline, Week 4, Week 8, Week…; Change From Baseline in National Eye Institute Visual Function Questionnaire-39 (VFQ-39) Score Standard Luminance — Ass…; Change From Baseline in Mean Low Luminance Questionnaire (LLQ) Score — Baseline (Day 0), Week 12, and Week 24 and Week…; Change From Baseline in Mean Mesopic Light Sensitivity — Baseline (Day 0) and Weeks 4,8,12,16,20,and 24; Change From Baseline in Mean Retinal Pigment Epithelium - Drusen Complex (RPEDC) Thickness as Measured by SD-OCT — Base…; Change From Baseline in Mean Retinal Pigment Epithelium-Drusen Complex Volume — Baseline (Day 0) to Week 24
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.